Ablynx: Difference between revisions
Filled in 3 bare reference(s) with reFill () |
Rescuing 1 sources and tagging 0 as dead. #IABot (v1.2.4) |
||
| Line 22: | Line 22: | ||
==History== |
==History== |
||
In November 2001, Ablynx was established as a spin-off of the [[Vlaams Instituut voor Biotechnologie]] (VIB) and the [[Free University of Brussels]] (VUB). Seed financing of €2M was provided by [[Gimv]].<ref>[http://www.ablynx.com/en/about-ablynx/history/ Ablynx.com - History]</ref> |
In November 2001, Ablynx was established as a spin-off of the [[Vlaams Instituut voor Biotechnologie]] (VIB) and the [[Free University of Brussels]] (VUB). Seed financing of €2M was provided by [[Gimv]].<ref>[http://www.ablynx.com/en/about-ablynx/history/ Ablynx.com - History] {{wayback|url=http://www.ablynx.com/en/about-ablynx/history/ |date=20120209041112 }}</ref> |
||
In July 2015 [[Merck & Co.]] and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/ablynx-merck-co-ink-4b-expansion-of-immuno-oncology-collaboration/81251532/|title=Ablynx, Merck & Co. Ink $4B+ Expansion of Immuno-Oncology Collaboration|work=GEN}}</ref> In 2015, the [[Novo Nordisk]] announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/novo-nordisk-joins-ablynx-in-up-to-399m-nanobody-alliance/81252025/|title=Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody® Alliance - GEN News Highlights - GEN|work=GEN}}</ref> |
In July 2015 [[Merck & Co.]] and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/ablynx-merck-co-ink-4b-expansion-of-immuno-oncology-collaboration/81251532/|title=Ablynx, Merck & Co. Ink $4B+ Expansion of Immuno-Oncology Collaboration|work=GEN}}</ref> In 2015, the [[Novo Nordisk]] announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/novo-nordisk-joins-ablynx-in-up-to-399m-nanobody-alliance/81252025/|title=Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody® Alliance - GEN News Highlights - GEN|work=GEN}}</ref> |
||
Revision as of 20:04, 2 October 2016
| ABLX[1] | |
| Industry | Biotechnology |
| Founded | 2001  |
| Headquarters | , Belgium |
Key people | Edwin Moses (CEO) Wim Ottevaere (CFO) |
| Website | www |
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.
History
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.[2]
In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx.[3] In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.[4]
References
Further reading
- Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
- De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
  | This Belgian company-related article is a stub. You can help Wikipedia by expanding it. |